Open Orphan PLC Result of AGM (7861T)

TIDMORPH

RNS Number : 7861T

Open Orphan PLC

22 July 2020

22 July 2020

Open Orphan plc

("Open Orphan" or the "Company")

Result of AGM

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce that at the Company's Annual General Meeting held today, all resolutions put to the meeting were duly passed.

For further information please contact

 
  Open Orphan plc                                  [phone] 
  Cathal Friel, Executive Chairman 
 
  Arden Partners plc (Nominated Adviser and        [phone] 
   Joint Broker)                                    5900 
  John Llewellyn-Lloyd / Benjamin Cryer / 
   Dan Gee-Summons 
 
                                                   [phone] 
  finnCap plc (Joint Broker)                        500 
  Geoff Nash / James Thompson/ Richard Chambers 
 
  Davy (Euronext Growth Adviser and Joint 
   Broker)                                         [phone] 
  Anthony Farrell 
 
                                                   [phone] 
  Camarco (Financial PR)                            4980 
  Tom Huddart / Hugo Liddy 
 

Notes to Editors - Open Orphan:

Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Conducted from Europe's only 24-bedroom quarantine clinic with onsite virology providing individually isolated rooms and connected to our specialist laboratory facility. Which offers highly specialised virology and immunology laboratory services to support pre-clinical and clinical respiratory drug, antiviral, and vaccine discovery and development. Reliable laboratory analysis underpinned by scientific expertise is essential when processing and analysing clinical samples. Robust quality processes support our team of scientists in the delivery of submission ready data.

The Company has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models. As announced in early March, Open Orphan is rapidly advancing a number of Coronavirus challenge study models and expects to be helping many COVID-19 vaccine development companies to test their vaccines. No other company in the world has such a portfolio, with only two competitors globally having 1 challenge study model each. In June 2020 hVIVO COVID Clear Test was launched, the most accurate antibody test available to UK employers, helping them to get their people back to work.

Open Orphan comprises of two commercial specialist CRO services businesses ( hVIVO and Venn ) and is developing an early stage orphan drug genomics data platform business. This platform captures valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools. In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls), preclinical, Phase I & II clinical trials design and execution. The merger with hVIVO created a European full pharma services company broadening the Company's customer base and with complementary specialist CRO services, widened the range of the Company's service offerings.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RAGPPUBWMUPUGGP

(END) Dow Jones Newswires

July 22, 2020 07:43 ET (11:43 GMT)